Significant weight gain was observed in ponsegromab-treated groups ... Cachexia: a condition of severe muscle wasting and weight loss. GDF-15: a protein linked to inflammation and tissue damage.

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with ... metabolic disorder that results in loss of muscle and fat in the body, and is often ...

Cachexia involves loss of appetite and weight, muscle-wasting ... blocks a hormone known as GDF-15 that regulates appetite and body weight. The patients in the trial had elevated levels of ...

Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary ...

the inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia symptoms, findings that confirmed the role of GDF-15 as a driver of ...

As well as negatively affecting quality of life, the condition is thought to directly cause up to 30% of cancer deaths because muscle loss leads to heart or respiratory failure. GDF-15 is elevated ...

The poster will highlight the potential of targeting Growth Differentiation Factor 15 (GDF-15) to enhance the activity and overcome resistance to ADC therapies, which are increasingly used as ...